News

A comprehensive review of management approaches for childhood sickle cell disease (SCD), focused on neonatal screening implementation, common complications, and current standard treatment, drew a primary conclusion that improvements in the care of patients transitioning from pediatric to adult patients is needed to reduce young adult mortality and hospital costs. The review article, titled…

Sickle cell anemia (SCA) is associated with lifelong complications and a high mortality rate in developing countries. Researchers have now developed a low-cost paper-based diagnostic test that allows clinicians to diagnose SCA earlier, significantly reducing the burden of the disease sickle cell anemia in resource-limited areas. The research paper, “Validation…

Global biopharma Bristol-Myers Squibb has joined the public-private Angola Sickle Cell Initiative to provide Angolan children who have sickle cell disease with an effective therapy unavailable to many patients in the West African country. The initiative is a collaborative project of the Angola Ministry of Health, the…

Researchers investigated the use of hydroxyurea, a drug approved to treat sickle cell anemia in adults, in young children in New York State who are receiving this treatment. The findings reveal that pediatric use of hydroxyurea is widespread and increasing, but that incomplete adherence may limit the treatment’s full disease-modifying effects. The study,…